# Pionyr Immunotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pionyr-immunotherapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.pionyrtx.com
- Total disclosed funding: $46M
- Latest round: Series B (Dec 7, 2017)
- Investors on record: 8

## About

Pionyr Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic solutions to satisfy unmet medical needs, particularly in the realm of oncology and complex health conditions.Founded in 2015, Pionyr Immunotherapeutics, Inc. operates from San Francisco, US, developing advanced immunotherapies. The company was co-founded by Max Krummel, who has a history of founding pharmaceutical enterprises. In June 2020, Gilead Sciences, Inc. acquired a 49.9 percent stake for USD 275.00 mn, leading to a full acquisition by Ikena Oncology, Inc. in August 2023. Pionyr has completed 6 deals in its operational timeline, accumulating a total amount raised of USD 275.00 mn.Pionyr Immunotherapeutics specializes in advanced therapeutic solutions aimed at addressing unmet medical needs within the biopharmaceutical sector. The company's core offerings focus on innovative treatments leveraging proprietary technologies to enhance the efficacy and safety of existing therapies. Their products cater to a diverse clientele, including hospitals and specialty clinics across North America and Europe, targeting rare diseases and complex health conditions to improve patient outcomes.Pionyr Immunotherapeutics generates revenue through partnerships with healthcare institutions and direct sales to specialized clinics. Their revenue model includes long-term agreements for the distribution of flagship therapeutic products and a subscription-based model for certain services, ensuring continuous access to their therapies. The company’s revenue streams are further supported by collaborations with research organizations and pharmaceutical companies, enhancing its market presence in the biopharmaceutical industry.The recent acquisition by Ikena Oncology will allow Pionyr Immunotherapeutics to bolster its targeted oncology programs and potentially introduce new products aimed at addressing cancer treatment. The specific upcoming product launches and timelines are not disclosed. The company plans to expand its market presence further, particularly focusing on oncology sectors in North America and Europe. The capital raised during the acquisition will support these growth initiatives, facilitating research and development efforts to advance their therapeutic offerings.

## Funding rounds

- Series B, Dec 7, 2017, $38M — New Enterprise Associates, OrbiMed Advisors, Sofinnova Investments, SV Health Investors, OUP (Osage University Partners), Mission Bay Capital, Vida Ventures, California Institute for Quantitative Biosciences
- Series A, Jan 4, 2017, $8M — OrbiMed Advisors, SV Health Investors, OUP (Osage University Partners), Mission Bay Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A, Series B
- Mission Bay Capital (https://capitalatlas.ai/funds/mission-bay-capital) — Series A, Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series B
- California Institute for Quantitative Biosciences — Series B